Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Invested Capital (2020 - 2023)

Cullinan Therapeutics has reported Invested Capital over the past 4 years, most recently at $468.8 million for Q3 2023.

  • Quarterly results put Invested Capital at $468.8 million for Q3 2023, down 20.01% from a year ago — trailing twelve months through Sep 2023 was $468.8 million (down 20.01% YoY), and the annual figure for FY2022 was $535.0 million, up 25.78%.
  • Invested Capital for Q3 2023 was $468.8 million at Cullinan Therapeutics, down from $499.6 million in the prior quarter.
  • Over the last five years, Invested Capital for CGEM hit a ceiling of $604.6 million in Q2 2022 and a floor of $89.5 million in Q3 2020.
  • Median Invested Capital over the past 4 years was $458.5 million (2021), compared with a mean of $392.9 million.
  • Biggest five-year swings in Invested Capital: soared 397.68% in 2021 and later dropped 20.01% in 2023.
  • Cullinan Therapeutics' Invested Capital stood at $200.3 million in 2020, then surged by 112.35% to $425.4 million in 2021, then increased by 25.78% to $535.0 million in 2022, then decreased by 12.38% to $468.8 million in 2023.
  • The last three reported values for Invested Capital were $468.8 million (Q3 2023), $499.6 million (Q2 2023), and $485.6 million (Q1 2023) per Business Quant data.